Skip to main content

Table 2 Summary of best tumor response according to prior anthracycline exposure

From: First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study

  No. of Pts No. of Responders Percent of Pts 95% CI
Evaluable patients 35 14 40.0% (23.8%–56.2%)
Prior anthracycline exposure     
   Yes 22 6 27.3% (8.7%–45.9%)
   No 13 8 61.5% (35.1%–88.0%)
  1. CI = confidence interval.